2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: L04

Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Abstract Number: 188

Pediatric Trainee Confidence and Exposure to Rheumatology
Abstract Number: 1461

Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts
Abstract Number: 2794

Peptidylarginine Deiminases Are Required for Normal Immunoglobulin G Half-Life
Abstract Number: 463

Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
Abstract Number: 2360

Perceptions of Patients with Rheumatoid Arthritis about Self-Assessment of Disease Activity after Watching an Educational Video: Qualitative Pilot Results from the Auto-DAS in Middle Eastern Arab Countries Study
Abstract Number: 2356

Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Abstract Number: 648

Performance of an Online Self-Referral Questionnaire Compared to a Physician-Based Referral Approach to Identify Patients with a High Probability of Axial Spondyloarthritis: Results from the Optiref Study
Abstract Number: 2694

Performance of Anti-Scl-70 Antibody Testing By Multiple-Bead, Enzyme-Linked Immunosorbent Assay, and Immunodiffusion in a University Setting
Abstract Number: 1599

Performance of Referral Strategies for Spondyloarthritis: A Population-Based Nationwide Study
Abstract Number: 2978

Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort
Abstract Number: 1473

Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Abstract Number: 2297

Performance of the New EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies (IIM) in a Large Monocentric IIM Cohort
Abstract Number: 1681

Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases
Abstract Number: 1957

Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].